keyword
MENU ▼
Read by QxMD icon Read
search

Radiopharmaceutical

keyword
https://www.readbyqxmd.com/read/28635637/a-short-term-biological-indicator-for-long-term-kidney-damage-after-radionuclide-therapy-in-mice
#1
Giovanni Pellegrini, Klaudia Siwowska, Stephanie Haller, Daniel J Antoine, Roger Schibli, Anja Kipar, Cristina Müller
Folate receptor (FR)-targeted radionuclide therapy using folate radioconjugates is of interest due to the expression of the FR in a variety of tumor types. The high renal accumulation of radiofolates presents, however, a risk of radionephropathy. A potential option to address this challenge would be to use radioprotectants, such as amifostine. Methods for early detection of kidney damage that-in this case-cannot be predicted based on dose estimations, would facilitate the development of novel therapies. The aim of this study was, therefore, to assess potentially changing levels of plasma and urine biomarkers and to determine DNA damage at an early stage after radiofolate application...
June 21, 2017: Pharmaceuticals
https://www.readbyqxmd.com/read/28632200/the-beginning-and-development-of-the-theranostic-approach-in-nuclear-medicine-as-exemplified-by-the-radionuclide-pair-86-y-and-90-y
#2
Frank Rösch, Hans Herzog, Syed M Qaim
In the context of radiopharmacy and molecular imaging, the concept of theranostics entails a therapy-accompanying diagnosis with the aim of a patient-specific treatment. Using the adequate diagnostic radiopharmaceutical, the disease and the state of the disease are verified for an individual patient. The other way around, it verifies that the radiopharmaceutical in hand represents a target-specific and selective molecule: the "best one" for that individual patient. Transforming diagnostic imaging into quantitative dosimetric information, the optimum radioactivity (expressed in maximum radiation dose to the target tissue and tolerable dose to healthy organs) of the adequate radiotherapeutical is applied to that individual patient...
June 20, 2017: Pharmaceuticals
https://www.readbyqxmd.com/read/28627323/perspective-of-%C3%AE-v%C3%AE-6-integrin-imaging-for-clinical-management-of-pancreatic-carcinoma-and-its-precursor-lesions
#3
Katja Steiger, Anna-Melissa Schlitter, Wilko Weichert, Irene Esposito, Hans-Jürgen Wester, Johannes Notni
ß6-integrin immunohistochemistry analysis of a large number of pancreatic ductal adenocarcinoma (PDAC, 383 primary tumors, 7 lymph node, and 8 distant metastases) and 34 pancreatic intraepithelial neoplasia (PanIN) specimens revealed a high prevalence of αvß6-integrin expression in PDAC primaries (88%) and in almost all metastases, as well as in PanIN (57%). These findings underscore the high potential of a novel αvß6-integrin targeting positron emission tomography (PET) radiopharmaceutical, Ga-68-Avebehexin, for early diagnosis of pancreatic cancer...
January 1, 2017: Molecular Imaging
https://www.readbyqxmd.com/read/28624290/feasibility-of-reducing-differences-in-estimated-doses-in-nuclear-medicine-between-a-patient-specific-and-a-reference-phantom
#4
Alexandra Zvereva, Helmut Schlattl, Maria Zankl, Janine Becker, Nina Petoussi-Henss, Yeon Soo Yeom, Chan Hyeong Kim, Christoph Hoeschen, Katia Parodi
The feasibility of reducing the differences between patient-specific internal doses and doses estimated using reference phantoms was evaluated. Relatively simple adjustments to a polygon-surface ICRP adult male reference phantom were applied to fit selected individual dimensions using the software Rhinoceros®4.0. We tested this approach on two patient-specific phantoms: the biggest and the smallest phantoms from the Helmholtz Zentrum München library. These phantoms have unrelated anatomy and large differences in body-mass-index...
June 14, 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28618064/technetium-99m-radiochemistry-for-pharmaceutical-applications
#5
REVIEW
Dionysia Papagiannopoulou
(99m) Tc is a widely used radionuclide and the development of (99m) Tc imaging agents continues to be in demand. This overview discusses basic principles of (99m) Tc radiopharmaceutical preparation and design, and focuses on the technetium-99m radiochemistry relevant to its medical applications. The (99m) Tc complexes are described based on the most typical examples in each category, keeping up with the state-of-the-art in the field. In addition, the main current strategies to develop targeted (99m) Tc radiopharmaceuticals are summarized...
June 15, 2017: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28612247/-18-f-fluorothymidine-pet-imaging-in-gliomas-an-update
#6
Alexandra Nikaki, George Angelidis, Roxani Efthimiadou, Ioannis Tsougos, Varvara Valotassiou, Konstantinos Fountas, Vasileios Prasopoulos, Panagiotis Georgoulias
Brain neoplasms constitute a group of tumors with discrete differentiation grades, and therefore, course of disease and prognosis. Magnetic resonance imaging (MRI) remains the gold standard method for the investigation of central nervous system tumors. However, MRI suffers certain limitations, especially if radiation therapy or chemotherapy has been previously applied. On the other hand, given the development of newer radiopharmaceuticals, positron emission tomography (PET) aims to a better investigation of brain tumors, assisting in the clinical management of the patients...
June 13, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28602965/-67-ga-labeled-deferoxamine-derivatives-for-imaging-bacterial-infection-preparation-and-screening-of-functionalized-siderophore-complexes
#7
Joseph A Ioppolo, Deanna Caldwell, Omid Beiraghi, Lisset Llano, Megan Blacker, John F Valliant, Paul J Berti
INTRODUCTION: Deferoxamine (DFO) is a siderophore that bacteria use to scavenge iron and could serve as a targeting vector to image bacterial infection where current techniques have critical limitations. [(67)Ga]-DFO, which is a mimetic of the corresponding iron complex, is taken up by bacteria in culture, however in vivo it clears too rapidly to allow for imaging of infection. In response, we developed several new DFO derivatives to identify those that accumulate in bacteria, and at sites of infection, and that could potentially have improved pharmacokinetics...
June 1, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28600835/-in-loop-11-c-co2-fixation-prototype-and-proof-of-concept
#8
Kenneth Dahl, Thomas L Collier, Ran Chang, Xiaofei Zhang, Oleg Sadovski, Steven H Liang, Neil Vasdev
Carbon-11 labelled carbon dioxide is the most common feedstock for the synthesis of positron emission tomography radiotracers, and can be directly used for (11) C-carbonylation. Herein, we report the development of an apparatus that takes advantage of "in-loop" technologies to facilitate robust and reproducible syntheses of (11) C-carbonyl-based radiotracers by [(11) C]CO2 -fixation. Our "in-loop" [(11) C]CO2 -fixation method is simple, efficient, and proceeds smoothly at ambient pressure and temperature. We selected model (11) C-carbonyl labelled carbamates as well as symmetrical and unsymmetrical ureas based on their widespread use in radiotracer design and our clinical research interests for proof-of-concept...
June 9, 2017: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28598690/in-vitro-evaluation-of-188-re-hedp-a-mechanistic-view-of-bone-pain-palliations
#9
Rohit Sharma, Chandan Kumar, Madhava B Mallia, Mythili Kameswaran, Haladhar D Sarma, Sharmila Banerjee, Ashutosh Dash
Skeletal metastasis is common in advanced stages of various cancers, particularly of the prostate and breast carcinoma. (188)Re-HEDP (1-hydroxyethane 1, 1-diphosphonic acid) is a clinically established radiopharmaceutical for bone pain palliation of osseous metastasis, and it takes advantage of high bone affinity. The present work aims at elucidating the possible mechanisms of cell killing by (188)Re-HEDP in osteosarcoma cells and biodistribution studies in mice.(188)Re-HEDP complex was prepared by using lyophilized HEDP kits prepared in-house...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28597119/highlights-lecture-eanm-2016-embracing-molecular-imaging-and-multi-modal-imaging-a-smart-move-for-nuclear-medicine-towards-personalized-medicine
#10
REVIEW
Eric O Aboagye, Françoise Kraeber-Bodéré
The 2016 EANM Congress took place in Barcelona, Spain, from 15 to 19 October under the leadership of Prof. Wim Oyen, chair of the EANM Scientific Committee. With more than 6,000 participants, this congress was the most important European event in nuclear medicine, bringing together a multidisciplinary community involved in the different fields of nuclear medicine. There were over 600 oral and 1,200 poster or e-Poster presentations with an overwhelming focus on development and application of imaging for personalized care, which is timely for the community...
June 8, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28596949/new-methodologies-for-the-preparation-of-carbon-11-labeled-radiopharmaceuticals
#11
REVIEW
Kenneth Dahl, Christer Halldin, Magnus Schou
PURPOSE: This short review aims to cover the more recent and promising developments of carbon-11 ((11)C) labeling radiochemistry and its utility in the production of novel radiopharmaceuticals, with special emphasis on methods that have the greatest potential to be translated for clinical positron emission tomography (PET) imaging. METHODS: A survey of the literature was undertaken to identify articles focusing on methodological development in (11)C chemistry and their use within novel radiopharmaceutical preparation...
2017: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28583275/benign-cutaneous-and-subcutaneous-lesions-on-fdg-pet-ct
#12
REVIEW
Ur Metser, Noam Tau
(18)F-FDG, the most commonly used PET radiopharmaceutical in clinical practice, can also accumulate in inflammatory and infectious conditions. This may account for false-positive PET findings when staging or restaging a patient with malignancy. As clinical use of FDG-PET-CT is increasing, nuclear medicine physicians are encountering a myriad of cutaneous and subcutaneous lesions, many of which are incidental and benign. The most common cause for the FDG avidity of these lesions is inflammation. Although a specific diagnosis may not always be possible, background clinical history and morphologic features of the lesion on CT may help narrow the differential diagnosis...
July 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/28575794/-99m-tc-labeled-psma-inhibitor-biokinetics-and-radiation-dosimetry-in-healthy-subjects-and-imaging-of-prostate-cancer-tumors-in-patients
#13
Clara Santos-Cuevas, Jenny Davanzo, Guillermina Ferro-Flores, Francisco O García-Pérez, Blanca Ocampo-García, Eleazar Ignacio-Alvarez, Edgar Gómez-Argumosa, Martha Pedraza-López
The prostate-specific membrane antigen (PSMA) is expressed in epithelial cells of the prostate and highly overexpressed in 95% of advanced prostate cancers. The aims of this study was to estimate the biokinetics and dosimetry of (99m)Tc-EDDA/HYNIC-iPSMA ((99m)Tc-labeled PSMA inhibitor) in eight healthy subjects and evaluate its usefulness as a tumor-imaging agent in eight prostate cancer patients. METHODS: (99m)Tc-EDDA/HYNIC-iPSMA was obtained from a lyophilized formulation with radiochemical purities >98%, determined by reversed-phase HPLC and ITLC-SG analyses...
May 25, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28575697/pet-ct-with-18-f-choline-physiological-whole-bio-distribution-in-male-and-female-subjects-and-diagnostic-pitfalls-on-1000-prostate-cancer-patients-18-f-choline-pet-ct-bio-distribution-and-pitfalls-a-southern-italian-experience
#14
Ferdinando Calabria, Agostino Chiaravalloti, Carmelo Cicciò, Vincenzo Gangemi, Domenico Gullà, Federico Rocca, Gianpasquale Gallo, Giuseppe Lucio Cascini, Orazio Schillaci
INTRODUCTION: The (11)C/(18)F-choline is a PET/CT radiopharmaceutical useful in detecting tumors with high lipogenesis. (11)C/(18)F-choline uptake can occur in physiological conditions or tumors. The knowledge of its bio-distribution is essential to recognize physiologic variants or diagnostic pitfalls. Moreover, few information are available on the bio-distribution of this tracer in female patients. Our aim was to discuss some documented (18)F-choline PET/CT pitfalls in prostate cancer patients...
April 17, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28559934/the-current-status-of-spect-or-spect-ct-in-south-korea
#15
REVIEW
Ikdong Yoo, Eun Kyoung Choi, Yong-An Chung
The first step to nuclear medicine in Korea started with introduction of the gamma camera in 1969. Although planar images with the gamma camera give important functional information, they have the limitations that result from 2-dimensional images. Single-photon emission computed tomography (SPECT) due to its 3-dimensional image acquisition is superior to earlier planar gamma imaging in image resolution and diagnostic accuracy. As demand for a hybrid functional and anatomical imaging device has increased, integrated SPECT/CT systems have been used...
June 2017: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28555448/new-synthesis-route-of-active-substance-d-l-hmpao-for-preparation-technetium-tc99m-exametazime
#16
Justyna Pijarowska-Kruszyna, Urszula Karczmarczyk, Antoni Włodzimierz Jaroń, Ewa Laszuk, Marcin Radzik, Piotr Garnuszek, Renata Mikołajczak
BACKGROUND: Technetium Tc99m Exametazime (99mTc-HMPAO) is currently used as a radiopharmaceutical for determining regional cerebral blood flow and for the labelling of autologous leucocytes for infection and inflammation imaging. The HMPAO ligand exists in two diastereomeric forms: d,l and meso. Usually, the substance is obtained in low chemical yield in a time consuming procedure. Furthermore, the final product still contains some amounts of the meso-form. The aim of this study was to develop the efficient, reliable and fast method for isolation of the d,l-HMPAO, which would provide the ligand with high purity and free from the meso-diastereomer...
2017: Nuclear Medicine Review. Central & Eastern Europe
https://www.readbyqxmd.com/read/28553184/initial-experience-in-the-use-of-technetium-99-metastable-hydroxymethylene-diphosphonate-as-an-alternative-ventilation-agent-during-periods-of-interim-shortage
#17
Colin Raymond Young, Kalpna Prasad
Sporadic supply interruptions of select radiopharmaceuticals on the global market require consideration of alternative agents to support continuity of essential nuclear medicine examinations. During an acute shortage of Xenon-133 and technetium-99 metastable (Tc-99m) diethylene-triamine-pentaacetate (DTPA), our institution used aerosolized Tc-99m hydroxymethylene diphosphonate (HDP), a radiopharmaceutical traditionally used in bone scintigraphy, in lieu of traditional ventilation agents, for two cases of suspected pulmonary embolism...
April 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28551301/hybrid-imaging-with-pet-mri-ready-for-clinical-routine
#18
EDITORIAL
Jiří Ferda
The introduction of integrated PET/MRI imaging combining full magnetic resonance imaging and positron emission tomography is a new milestone in tissue imaging. As usual innovations in clinical practice generate new dilemmas. The questions it poses are: when to use PET/MRI scanning, what radiopharmaceutical to use and how to optimize examination protocols. A range of new radiopharmaceuticals, in addition to 18F-fluorodeoxyglucose (18F-FDG), are now available for assessing and characterizing tissues.
May 9, 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28546335/radiopharmaceuticals-for-therapy
#19
Dao Le
No abstract text is available yet for this article.
May 25, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28545366/role-of-positron-emission-tomography-for-central-nervous-system-involvement-in-systemic-autoimmune-diseases-status-and-perspectives
#20
Daniele Mauro, Gaetano Barbagallo, Salvatore D'Angelo, Sannino Pasqualina, Saverio Naty, Caterina Bruno, Ignazio Olivieri, Rosa Daniela Grembiale, Francesco Ursini
In the last years, an increasing interest in molecular imaging has been raised by the extending potential of positron emission tomography (PET). The role of PET imaging, originally confined to the oncology setting, is continuously extending thanks to the development of novel radiopharmaceutical and to the implementation of hybrid imaging techniques, where PET scans are combined with computed tomography (CT) or magnetic resonance imaging(MRI) in order to improve spatial resolution. Early preclinical studies suggested that 18F-FDG PET can detect neuroinflammation; new developing radiopharmaceuticals targeting more specifically inflammation-related molecules are moving in this direction...
May 23, 2017: Current Medicinal Chemistry
keyword
keyword
29071
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"